-
A Study of the Safety and Effectiveness of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution for Non-Infectious Anterior Uveitis
Rochester, MN
The purpose of this study is to compare the safety and effectiveness of ocular (eye) iontophoresis with dexamethasone phosphate eye drops (EGP-437) versus prednisolone acetate (1%) eye drops in patients with a non-infectious inflammation inside the eye.
-
A Study to Assess the Effectiveness and Safety of Intravitreal 440 ug DE-109 Sirolimus Injections for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
Jacksonville, FL
The purpose of this study is to assess the effectiveness and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS). There is a 6-month, single-arm, open-label period after completion of the 6-month double- masked, controlled period allows the evaluation of the efficacy and safety of intravitreal injection of DE-109 440 µg every 2 months for longer duration than appropriate for a placebo or sham control.
-
Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis
Rochester, MN
The purpose of this study is to evaluate the efficacy of gevokizumab in the treatment of active non-infectious intermediate, posterior, or pan- uveitis.
-
A Study Assessing the Effectiveness and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
Rochester, MN
The purpose of this study is to assess the effectiveness and safety of DE-109 440 µg every 2 months in subjects with active, non-infectious uveitis of the posterior segment of the eye (NIU-PS). There is a 6-month, single-arm, open-label period after completion of the 6-month double- masked, controlled period allows the evaluation of the efficacy and safety of intravitreal injection of DE-109 440 µg every 2 months for longer duration than appropriate for a placebo or sham control.
-
Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial
Rochester, MN
The Macular Edema Ranibizumab v. Intravitreal anti-inflammatory Therapy (MERIT) Trial will compare the relative efficacy and safety of intravitreal methotrexate, intravitreal ranibizumab, and the intravitreal dexamethasone implant for the treatment of uveitic macular edema persisting or reoccurring after an intravitreal corticosteroid injection. MERIT is a parallel design (1:1:1), randomized comparative trial with an anniversary close-out at the 6 month clinic visit. The primary outcome is percent change in central subfield thickness from the baseline OCT measurement to the 12 week visit.
-
Outcome Measures for Clinical Trials in Pediatric Eye Care and Strabismus
Rochester, MN
This study is being done to:
- Assess what children with different eye conditions experience in everyday life
- Improve our understanding of the difficulties that children with eye problems experience
- Improve reporting of how parents see their child’s eye condition affecting them
- Assess what parents of children with different eye conditions experience in their own everyday life
- Improve the way we assess the benefits of treatment